|
N Y Medical College Protocols |
| Protocol Report | |
| RTOG 94-02 | Phase III Intergroup randomized comparison of radiation alone vs. pre-radiation chemotherapy for pure and mixed anaplastic oligodendrogliomas. |
| RTOG 93-05 | Phase III trial comparing the use of radiosurgery followed by conventional radiotherapy with BCNU for supratentorial glioblastoma multiforne. |
| RTOG 95-08 | Phase III trial comparing the whole brain irradiation with versus without stereotactic radiosurgery boost for patients with one to three unresected brain metastases. |
| RTOG 94-08 | Phase III trial of the study of endocrine therapy used as a cytoreductive and cytostatic agent prior to radiation therapy in good prognosis locally confined adenocarcinoma of the prostate (BRT boost not allowed). |
| RTOG 95-12 | A Randomized Study of hyper fractionation versus conventional fraction in T2 squamous cell carcinoma of the vocal cord. |
| RTOG 96-16 | Phase III Study of adjuvant chemotherapy after resection for patients with T2N0 stage 1 non-small cell carcinoma of the lung. |
| RTOG 97-14 | Randomized trial of palliative radiation therapy for osseous metastases. A study of palliation of symptoms and quality of life. |
| RTOG 99-15 | Randomized trial of post-mastectomy radiotherapy in stage II breast cancer in women with one or three positive axillary nodes. |
| RTOG 99-02 | Phase III protocol of Androgen Suppression (AS) and radiation therapy (RT) followed by chemotherapy with paclitaxel, estramustine and etoposide (TEE) for localized, high-risk, prostate cancer. |
| RTOG 99-05 | Phase III study of adjuvant postoperative irradiation with or without Cisplatin/Taxol chemotherapy following TAH/BSO for patients with endometrial cancer. |
| RTOG 98-04 | Phase III trial of Tamoxifen alone Vs Tamoxifen plus RT for good risk duct carcinoma insitu (DCIS) of the female breast. |
| RTOG 98-09 | Phase III study of Pentosanpolysulfate (PPS) in treatment of GI tract seqelae of radiotherapy. |
| RTOG 98-02 | Phase II study of observation in favourable low-grade glioma and phase III study of radiation with or without PCV chemotherapy in unfavorable low-grade glioma. |
| RTOG 98-03 | PhaseI/II radiation dose escalation study applying conformal radiation therapy in Supratentorial Glioblastoma Multiforme 3D brain. |
| RTOG 97-12 | Phase I Dose escalation study of thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer. |
| RTOG 97-04 | Phase III study of pre resected pancreatic adenocarcinoma and post chemoradiation 5-fu Vs. pre and post chemoradiation gemcitabine for postoperative adjuvant treatment. |
| RTOG 98-01 | Phase III randomized study of Amifostine Muscosal Protection for patients with favourable performance inoperable stage II-III A/B non-small cell lung cancer (NSCLC) receiving sequential induction and concurrent hyper fractionated radiotherapy with paclitaxel and carboplatin. |
| RTOG 98-11 | Phase III randomized study of 5-Fluorouracil, Mitomycin-C and radiotherapy versus 5-Fluorouracil, Cisplatin and radiotherapy in carcinoma of anal canal. |
| RTOG 99-10 | Phase III trial to evaluate the duration of Neoadjuvant total Androgen Suppression (TAS) and radiation therapy (RT) in intermediate-risk prostate cancer. |
| RTOG 99-11 | Phase II study of Paclitaxel and Cisplatin in combination with split course concomitant hyper fractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck. |
| RTOG 99-03 | A randomized phase III trial to assess the effect of erythropietin on local-regional control in anemic patients treated with radiotherapy for carcinoma of the head and neck. |
| RTOG 99-04 | Phase II trial of preoperative chemotherapy and chemo radiotherapy for potentially respectable adenocarcinoma of the stomach. |
| RTOG 00-15 | A randomized phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin in clinical stage 1B (T2N0), II (T1-2N, T3N0) and selected IIIA (T3N1) non-small cell lung cancer (NSCLC). |
| RTOG 98-13 | Phase I/III randomized study of radiation therapy and temozolomide versus radiation therapy and BCNU versus radiation therapy and temozolomide and BCNU for anaplastic astrocytoma. |
| Children Cancer Group | |
| CCG - 59704 | Pilot Study for the treatment of children with newly diagnosed advance state hodgkin's disease - Up front intensive chemotherapy. |
[zalmen a. arlin cancer institute investigational protocols]
INVESTIGATIONAL PROTOCOLS (ADULT SERVICES)
BREAST
"A Clinical Trial to Determine the Efficacy of a Dietary Fat Reduction Program Provided in Addition to Systemic Adjuvant Therapy in the Management of Patients with Primary Invasive Breast Cancer" (WINS) P.I.: H. Chun
"Phase III Double-Blind, Placebo-Controlled, Prospective Randomized Comparison of Adjuvant Therapy with Tamoxifen vs. Tamoxifen and Fenretinide in Postmenopausal Women with Involved Axillary Lymph Nodes and Positive Receptors" P.I.: H. Chun
"A Multicenter, Open-Label, Randomized Study of Three Schedules of Weekly Taxol Induction Therapy Followed by Weekly Taxol Maintenance Therapy in Metastatic Breast Cancer Patients" P.I.: H. Chun
GI
Phase I Clinical Study of Every Three Week Irinotecan with Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients with Gastrointestinal and Other Solid Malignancies P.I.: H. Chun
"Colorectal Adenoma Chemoprevention Trial Using Aspirin: A Phase III Study" P.I.: H. Chun
"A Randomized Open_label Phase III Study of a 28-Day Oral Regimen of 5-Fluorouracil Plus 776C85 Versus Intravenous 5-Fluorouracil plus Leucovorin as First-Line Theraphy in Patients with Metastatic/Advanced Colorectal Cancer" P.I.: H. Chun
"Multicenter Study Evaluating the Addition of Oxaliplatin to 5-Fluorouracil Based Chemotherapy in Subjects with Advanced Refractory Colorectal Cancer" P.I.: H. Chun
"A Compassionate Use Study of Oxaliplatin for Previously Treated Colorectal Cancer Patients" P.I.: H. Chun
"A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel Administered to Patients with Unresectable Intrahepatic Colorectal Metastases" P.I.: H. Chun
"A Phase II Trial of Paclitaxel Administered as a Weekly One Hour Infusion in Patients with Advanced Esophageal Cancer" P.I.: H. Chun
"A Combination Chemotheraphy with Cisplatin, Fluorouracil, Paclitaxel and Filgrastim in Patients with Adenocarcinoma of the Stomach and Gastroesophageal Junction - A Pilot Trial" P.I.: H. Chun
"A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel Administered to Patients with Unresectable Primary Hepatocellular Carcinoma" P.I.: H. Chun
"A Phase II Study of DOXIL (Liposomal Doxorubicin) in Patients with Advanced Hepatocellular Carcinoma or Cholangiocarcinoma" P.I.: H. Chun
LUNG
"A Large-Scale Trial Evaluating Adjuvant Chemotherapy After Curative Resection of Non-Small Cell Lung Cancer" P.I.: H. Chun
"A Phase II Study of Taxol Plus Carboplatin in Patients with Advanced, Recurrent, Metastatic Non-Small Cell Lung Cancer" P.I.: H. Chun
"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Evaluation of BAY 12-9566 in Patients with Stage IIIa or IIIb Non-Small Cell Lung Cancer" P.I.: H. Chun
"A Randomized Phase III Etoposide Study Comparing Etoposide and Cisplatin with Etoposide, Cisplatin and Paclitaxel in Patients with Extensive Small Cell Lung Cancer" P.I.: H. Chun
"A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma" P.I.: H. Chun
LYMPHOMA
"A Phase I/II Evaluation of Topotecan in Combination with Etoposide in Relapsed or Refractory Intermediate Grade and High Grade Non-Hodgkin's Lymphoma Patients" P.L:T. Ahmed
"Phase II Study of 9-Aminocamptothecin in Previously Treated Hodgkin's Disease and Non-Hodgkin's Lymphoma: IWF Grades A-H" P.I.: T. Ahmed
MELANOMA
"A Randomized Phase II Trial of Two Schedules of Paclitaxel in Advanced Melanoma" P.I.: C. Puccio
"A Randomized Phase II/III Trial of SCH 54031 PEG Interferon Alpha-2b (PEG Intron) vs. INTROn A as Adjuvant Therapy for Melanoma" P.I.: H. Chun
MESOTHELIOMA
"A Multicenter Randomized Comparative Phase III Trial of Onconase vs. Doxorubicin in Patients with Malignant Mesothelioma" P.I.: H. Chun
OVARIAN/GERM CELL
"A Phase II Trial of Taxotere, Topotecan and Filgrastim in Patients with Recurrent or Refractory Ovarian Cancer" P.I.: C. Puccio
A Phase 3 Study of PSC 833 in Combination with Paclitaxel and Carboplatin (PC-PSC) versus Paclitaxel and Carboplatin (PC) Alone in Patients with Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Cancer of the Peritoneum" P.I.: C. Puccio
A Phase I/II Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients with <2 cm Residual Disease Following Surgery P.I.: T. Ahmed
PANCREATIC
"A Phase II Study of Gemcitabine and Irinotecan HCl in Patients with Advanced Metastatic Pancreatic Cancer" P.I.: H. Chun Phase III Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) Versus Most Appropriate Chemotheraphy in Refractory Pancreatic Cancer Patients P.I.: H. Chun
Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients that have Progressive Disease Following Gemcitabine HCl Treatment P.I.: H. Chun
PROSTATE
"A Phase II Study of a Mitoxantrone-Estramustine Combination in Metastatic Prostate Cancer" P.I.: R. Kancherla
"A Phase II Open-Label Study of LDI-200 in Patients with Hormone-RefractoryProstate Cancer" P.I.: C. Puccio
A Phase II Study of Doxorubicin and Cyclophosphamide with Sequential Docetaxel in Patients with Hormone-Refractory Prostate Cancer P.I.: C. Puccio
RENAL CELL
"An Open Label Treatment Investigation of Catrix Oral Capsules in Patients with Renal Cell Carcinoma" Lescarden Corp. P.I.: C. Puccio
SUPPORTIVE
"Efficacy and Tolerability of 2.5 mg Itasetron with 20 mg Dexamethasone Intravenously and 32 mg Ondansetron with 20 mg Dexamethasone Intravenously in the Prevention of Vomiting and Nausea in Patients Undergoing Cisplatin (>75mg/m2) Containing Chemotherapy. A Randomized, Double-Blind, Multicenter, Parallel-Group Comparison" P.I.: T. Ahmed
"Randomized Study of Procrit in Non-Hodgkin's Lymphoma Patients with Anemia After Bone Marrow or Stem Cell Transplantation and High Dose Chemotherapy" P.I.: T. Ahmed
"Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Efficacy and Safety Study of IB-367 for the Prevention of Oral Mucositis in Patients Who Are Undergoing Myeloablative Conditioning Regimens" P.I.:R. Kancherla
A Multicenter, Open-Label, Randomized, Active Controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients with Acute or Chronic Leukemia P.I.: K. Seiter
An Open-Label, Single-Arm Clinical Trial of the Safety and Efficacy of Recombinant Tissue Plasminogen Activator (rt-PA) for the Restoration of Function to Central Venous Access Devices P.I.: T. Ahmed
HEMATOLOGIC MALIGNANCIES
Leukemia
aml
"Phase I/II Study of Paclitaxel, Cytarabine and All-Trans Retinoic Acid in Patients with Acute Leukemia" P.I.: K. Seiter
"Induction Therapy with Mitoxantrone, High Dose Cytarabine, Etoposide and All-Trans-Retinoic Acid in Patients with Acute Myelogenous Leukemia" P.I.: K. Seiter
"A Randomized, Open-Label Multicenter Phase II Trial to Assess the Safety, Tolerance and Preliminary Evidence of Efficacy of HuM195 Administered to Patients with Refractory or Relapsed Acute Myelogenous Leukemia" P.I.: K. Seiter
"A Multicenter Phase I Study of Oral N-Acetyl Dinaline (CI-994) in the Treatment of Patients with Acute Myeloid Leukemia" P.I.: K. Seiter
"Phase I/II Study of Topotecan, Cytarabine and Mitoxantrone in Patients with Acute Leukemia" P.I.: K. Seiter
"A Phase III, Open-Label, Randomized, Comparative Study of Topotecan, Ara-C (TAG) versus Idarubicin, Ara-c and G-CSF (IDAG) in MDS Patients with RAEB (High Risk), RAEB-t, or in Patients with AML from a Preceding Phase of MDS" P.I.: K. Seiter
"A Randomized Multicenter Phase II/III Trial to Assess the Safety, Tolerance and Preliminary Efficacy of HuM195 as Maintenance Therapy in Elderly Patients with AML in Complete Remission Following Chemotherapy" P.I.: K. Seiter
all
"A Phase III Trial Comparing Ara-C, High-Dose Mitoxantrone (ALL-2) to a Standard Vincristine/Prednisone Based Regimen (L-20) as Inductgion Therapy for Adult Patients with Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol" P.I.: K. Seiter
Phase I/II Study of Topotecan, Cytarabine and Mitoxantrone in Patients with Acute Leukemia" P.I.: K. Seiter
cll
:A Multicenter Phase 2 Study of Oral N-Acetyl Dinaline (CI-994) in the Treatment of Patients with Chronic Lymphocytic Leukemia" P.I.: K. Seiter
"A Randomized Phase II Study of Concurrent Fludarabine + Chimeric Anti-CD20 Monoclonal Antibody IDEC-C2B8 (Rituximab) Induction Followed by Rituximab Consolidation versus Fludarabine Induction Followed by Rituximab Consolidation in Untreated Patients with B-Cell Chronic Lymphocytic Leukemia" P.I.: K. Seiter
cml
"Subcutaneous Interferon-Alfa-2b and Low-Dose Cytarabine (LoDAC) Compared to Interferon Alfa-2b Only After Cytoreduction with Hydroxyurea in Chronic Phase Leukemia" P.I.: K. Seiter
Phase II Study of Topotecan in Patients with Chronic Myeloid Leukemia in Accelerated or Blast Phase" P.I.: K. Seiter
"A Randomized Phase II/III Trial of SCH 54031 PEG12000 Interferon alfa-2b (PEG Intron) vs. INTRON® A in Subjects with Newly Diagnosed CML" P.I.: K. Seiter
mds
"An Open-Label Randomized Phase III Comparison of LDI-200 and Observation in Patients with Myelodysplastic Syndromes" P.I.: K. Seiter
"Phase I/II Study of Topotecan in Myelodysplastic Syndromes" P.I.: K. Seiter
"A Phase III, Open-Label, Randomized, Comparative Study of Topotecan, Ara-C (TAG) versus Idarubicin, Ara-c and G-CSF (IDAG) in MDS Patients with RAEB (High Risk), RAEB-t, or in Patients with AML from a Preceding Phase of MDS" P.I.: K. Seiter
1998-99 INVESTIGATIONAL TRIALS (PEDIATRICS)
Phase II Trial of Oral Topotecan in Relapsed Acute Childhood Leukemia. P.I.: C. Sandoval
all
Treatment of Newly Diagnosed ALL in Children with a Poor Prognosis excluding Infants and Patients with Lymphoma-Leukemia or FAB L3 Blasts. P.I.: S. Jayabose
A Randomized Comparison of Intravenous vs Oral Mercaptopurine and Dexamethasone vs Prednisone for the Treatment of Favorable Prognosis ALL. P.I.: O. Tugal
BMT vs Prolonged Intensive Chemotherapy for Children with ALL after an Initial Bone Marrow Relapse. P.I.: O. Tugal
Extramedullary Relapse and Occult Marrow Involvement in Childhood ALL. P.I.: F. Ozkaynak
Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and Methothrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia Treatment of Newly Diagnosed ALL in Infants <1 year of age. P.I.: F. Ozkaynak
Treatment of Patients with All with Unfavorale Features. P.I.: F. Ozkaynak
aml
Treatment of Children <21 with Newly Diagnosed ANLL and Myelodysplastic Syndrome P.I.: S. Jayabose
AML Salvage Therapy for Patients in First Relapse or who Fail to Achieve an Initial Remission or who Develop AML as a Second Malignant Neoplasm. P.I.: C. Sandoval
A Phase III Study in Children with Untreated AML or MDS. P.I.: F. Ozkaynak
Treatment of Children with DS and AML, MS and TMD. P.I.: C. Sandoval
Neuroblastoma
Treatment for Infants and Children with Intermediate Risk Neuroblastoma Randomized Treatment of Recurrent Neuroblastoma with Topotecan Regimens Following Desferrioxamine (POG only) in an Investigational Window. P.I.: O. Tugal
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma. P.I.: O. Tugal
Wilms' Tumor Studies
Phase II Trial of ATRA/IFN-alpha2a in Children with Recurrent NBL or Wilms' Tumor. P.I.: O. Tugal National Wilms' Tumor Late Effects Study. P.I.: C. Sandoval National Wilms' Tumor Study V - Treatment of Relapsed Patients.
P.I.: C. Sandoval
Lymphoma
Treatment of Newlyh Diagnosed Disseminated Lymphoblastic Lymphoma and T-Large Cell Lymphoma. P.I. O. Tugal
Comprehensive Study of Clinically staged Hodgkin's Disease FAB LMB 96 Treatment of Mature B-Cell Lymphoma/Leukemia (A SFOP/CCG/UKCCSG Cooperative Study). P.I.: C. Sandoval
Pilot Study for the Treatment of Children with ND Advanced Stage Hodgkin's Disease. P.I.: O. Tugal
Rhabdomyosarcoma
Actinomycin-D and Vincristine with or without Radiation Therapy for Newly Diagnoseed Patients with Low-Risk Rhabdomyosarcoma or Undifferentiated Sarcoma: IRS-V Protocol. P.I.: C. Sandoval
A Phase II Study of CPT-II followed by multimodal, multiagent therapy for Patients with Newly Diagnosed Stage 4/Group IV RMS. P.I.: C. Sandoval
Soft Tissue
A Study of High Risk Malignant Germ Cell Tumors in Children. P.I.: S. Jayabose Phase III Intergroup Protocol for the Treatment of Children with Hepatoblastoma. P.I.: F. OzkaynakBrain
Multiagent Chemotherapy and Deferred Radiotherapy in Infants with Malignant Brain Tumors. P.I. F. Ozkaynak
Study of Neoadjuvant Chemotherapy Followed by Craniospinal Hyperfrac-tionated XRT in Patients With Newly Diagnosed High Risk PNET. P.I.: O. Tugal
Study of High Dose Pre-Irradiation Chemotherapy in Children with Newly Diagnosed High-Grade Astrocytoma. P.I.: C. Sandoval
Pre-Radiation Chemotherapy in Primary High Risk Brain Stem Tumors A phase II trial of Pre-XRT chemotherapy (VCR, CDDP, CPM, VP-16) for Children with Newly Diagnosed Intracranial Ependymoma P.I.: F. Ozkaynak
Study of Stereotactic Radiosurgery for Recurrent Brain Tumors Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old. P.I.: C. Moorthy
Phase II Prospective Randomized Study of Craniospinal RT Follow by 1 of 2 Adjuvant Chemotherapy Regimens for Newly Diagnosed Average Risk Medullo-blastoma. P.I.: O. Tugal
Group-Wide I/II Pilot Study of Concurrent Cisplatin, Vincristine, and RT Followed by Adjuvant Chemotherapy in Children with Newly-Diagnosed High-Risk CNS Embryonal Tumor. P.I.: O. Tugal
A Phase II Study of Temodal (SCH 52365, Temozolomide IND # 44162) in Children and Adolescents with Recurrent CNS Tumors: A CCG/POG Intergroup Protocol. P.I.: O. Tugal
A Phase II Trial of the Combination of Carboplatin and RMP-7 in Childhood Brain Tumors. P.I.: S. Jayabose
BONE MARROW/STEM CELL TRANSPLANTATION (ADULT & PEDIATRIC)
Breast
"Docetaxel, Doxorubicin, Cyclophosphamide Combination as a Standard Dose Treatment Prior to Dose-Intensive Chemotherapy in Patients with High-Risk Stage II/IIIA Breast Cancer" P.I.: T. Ahmed
"A Phase II Evaluation of Multiple Cycles of High Dose Chemotherapy Supported with Filgrastim and Peripheral Blood Progenitor Cells in Patients with Metastatic Breast Cancer" P.I.: T. Ahmed
"Dose-Intensive Chemotherapy Following standard Treatment in Patients with High-Risk Stage II/IIIA Breast Cancer" P.I.: T. Ahmed
"Dose-Intensive Chemotherapy with Peripheral Stem Cell Transplant Followed by Interferon Maintenance in Patients with Stage IV Breast Cancer" P.I.: T. Ahmed
"Peripheral Stem Cell Transplant Following Positive CD34+ Cell Selection in Stage IV Breast Cancer" P.I.: T. Ahmed
"High-Dose Chemotherapy with Peripheral Stem Cell Rescue for Patients with Advanced Breast Cancer: A Pilot Trial of a Combination of Vinorelbine, Ifosfamide/Mesna and Etoposide (VIME)" P.I.: H. Chun
cns
"A Trial of Intensive Chemotherapy and Autologous Stem Cell Support for Patients with Grade II and Grade III Glioblastoma Multiforme" P.I.: A. Mannancheril
"Peripheral Blood Stem Cell Transplant Following Positive CD34+ Cell Selection in Neuroblastoma" P.I. F. Ozkaynak
"Intensive/Sequential Chemotherapy & Autologousd Bone Marrow Transplant as Retrieval Therapy in Children with Recurrent or or Unresponsive Wilms' Tumor (POG)" P.I.: S. Jayabose
leukemia
"Autologous Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia" P.I.: R. Kancherla
lymphoma
"A Trial of Alternating Sequential Intensive Chemotherapy with Autologous Stem Cell Support in Intermediate-High and High Risk Large Cell and Diffuse Mantle Cell Lymphoma" P.I.: T. Ahmed
"A Randomized Study Comparing Interferon Alfa-2b vs. Placebo in Patients with Intermediate or High Grade Non-Hodgkin's Lymphoma in Complete or Partial Remission Following Salvage Therapy" P.I.: T. Ahmed
"A Study of Single or Sequential Dose-Intensive Treatment in Non-Hodgkin's Lymphoma" P.I.: T. Ahmed
"A Study of Single or Sequential Autologous Bone Marrow Transplant According to Previous Tumor Response in Relapsed or Refractory Hodgkin's Disease" P.I.: T. Ahmed
Pilot Study of Peripheral Blood Stem Cell Transplant following CBV Preparative Therapy in Children with Relapsed of Primarily Refractory HD and NHL. P.I.: F. Ozkaynak
Myeloma
"Sequential High-Dose Treatment and Interferon Maintenance in Myeloma Patients Resistant to Alkylating Agents" P.I.: T. Ahmed
"Allogeneic Peripheral Stem Cell Transplantation and Interferon Maintenance in Resistant or Refractory Myeloma" P.I.: T. Ahmed ovarian/germ cell (Note: SUBHEAD)
"High Dose Chemotherapy With Autologous Bone Marrow Rescue for Advanced Ovarian Cancer and Germ Cell Tumors" P.I.: T. Ahmed
"High Dose ThioTEPA, Topotecan and Carboplatin (TTP) Combination Followed by Stem Cell Transplantation in Patients with Advanced or Relapsed Ovarian Cancer" P.I.: T. Ahmed
solid tumor
"A Comparative Study of GM-CSF Given With or Without Peripheral Stem Cell Support Following Dose-Intensive Chemotherapy in Recurrent or Refractory Lymphoma, Recurrent or Refractory Ovarian Cancer and Responsive Small-Cell Lung Cancer" P.I.: T. Ahmed
"A Phase I/II Study of Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Solid Tumors with Preparatory Regimen of Amifostine, Melphalan, Carboplatin, Etoposide and Escalating Doses of Cyclophosphamide" P.I.: F. Ozkaynak.
Intensive/Sequential Chemotherapy & Autologous BMT as Retrieval Therapy in Children with Recurrent or Unresponsive Wilms' Tumor (POG-9445)
"Phase III Study of Multiple Courses of Melphalan and Carboplatin with Stem Cell Support in Relapsed, Refractory or Progressive Tumors in Patients with Poor Risk Solid Tumors" P.I.: F. Ozkaynak
"Phase II Study of ABMT in Pediatric Solid Tumors with a Preparatory Regimen of Melphalan, Carboplatin, VP-16 and Escalating Doses of Cyclophosphamide" P.I.: F. Ozkaynak
"Tandem Peripheral Blood Stem Cell Transplantation with High-dose ThioTEPA and Carboplatin in Relapsed, Refractory or Progressive Pediatric Solid Tumors" P.I.: F. Ozkaynak
broad-based/supportive regimens
"Bone Marrow Transplantation Using Non-T-Depleted Marrow From Sibling Donors" P.I.: K. Seiter
"Donor Leukocyte Infusions in Patients with Recurrent or Persistent Hematologic Malignancies After Allogeneic Bone Marrow Transplantation" P.I.: T. Ahmed
"A Pilot Study of Neonatal Cord Blood Stem Cells in the Treatment of Hematologic and Genetic Disorders" P.I.: T. Ahmed
"Cytokine-Mobilized Allogeneic Peripheral Stem Cell Transplantation in Children-A Pediatric Blood and Marrow Transplant Consortium Study" P.I.: F. Ozkaynak
"Unrelated Hematopoeitic Stem Cell Transplantation for Life-Threatening Hemphagocytic Disorders" P.I.: F. Ozkaynak
"A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Lisofylline in Patients Undergoing Bone Marrow Transplantation from Unrelated Donors" P.I.: T. Ahmed
"Marrow Purging with Etoposide for Patients with Marrow Involvement with Advanced Cancer" P.I.: T. Ahmed
"Marrow Depletion with Monoclonal Antibodies Prior to Transplantation for Patients with Advanced Hematologic Malignancy" P.I.: T. Ahmed
"T-Cell Depletion for the Prevention of Graft vs. Hose Disease" P.I.: T. Ahmed
A Multicenter, Randomized, Controlled Clinical Study to Validate the Safety and Effectiveness of the Aastrom Replicell Cell Production System for Reduction of PBSC Cell Dose in Autologous Stem Cell Therapy P.I.: T. Ahmed
"Bone Marrow Transplantation Using Non-T-Depleted Marrow From Unrelated Donors" P.I.: K. Seiter
[PI=Principal Investigator, Physician responsible for coordinating a clinical trial.]
For more information about our clinical trials program, call 914-4-CANCER.
[glossary of terms]
| Reference Date: | Definite starting date of Cancer Registry data collection. All cancer cases diagnosed or treated at WMC after this date must be included in the database. |
| Accessioned: | Entered into the Cancer Registry database by year first seen at WMC for each new primary cancer. |
| Analytic Case: | Case which was first diagnosed and/or received all or part of first course of treatment at this hospital. |
| Non-Analytic Case: | Case seen at this facility for recurrent or metastatic disease, after all of the first course of treatment was completed elsewhere. Cases first diagnosed at autopsy. |
| First Course of Treatment: | Initial tumor directed treatment(s) usually initiated within four months after diagnosis. For leukemia, treatment initiated within two months of diagnosis. |
| Extent of Disease/Stage: | Determined at the time of initial treatment. Stage assigned according to SEER Summary Staging Guide or; AJCC-TNM Staging System. |
| In-Situ: | Tumor meets all microscopic criteria for malignancy except invasion. |
| Localized: | Tumor is confined to the organ of origin. |
| Regional: | Tumor has spread by direct extension to immediately adjacent organs or tissue and/or metastasized to regional lymph nodes. |
| Distant: | Tumor has spread beyond immediately adjacent organs or tissues by direct extension and/or has either developed secondary or metastatic tumors or metastasized to distant lymph nodes or organs. |
| Systemic: | Cancer of the hematopoietic system as a whole. |
| Unknown: | Tumor classification used when stage cannot be determined from information available or medical authority. |
| American Joint Committee on Cancer TNM Staging: | Staging classification scheme based on the premise that cancer of similar histology or site of origin share similar patterns of growth and extension: (T) Tumor size, (N) Nodal involvement and (M) Distant metastases. |
| SEER: | Surveillance, Epidemiology and End Results, branch of NCI. |
| NCDB: | National Cancer Data Base, project of American College of Surgeons and American Cancer Society. |
| NOS: | Not Otherwise Specified. |
| Non-Reportable: | Patients with a history of malignancy only or seen for consult only, are excluded from the registry database in accordance with the American College of Surgeons' guidelines. |
| Metastases: | Change in location of disease of its manifestation or transfer from one organ or part to another, not directly connected. |
| Palliative: | Therapy that relieves symptoms such as pain without altering the disease course. |
| Address: Department of Radiation Medicine, Zalmen A. Arlin Cancer Institute, Westchester Medical Center, 95 Grasslands Road, Valhalla, NY 10595, Phone: 914-493-8561, Email: info@cancerdocs-radiation.com |